Waiting Time Policies in the Health Sector

More from Office of Health Economics

Annual lecture

Office of Health Economics

Devlin ispor 2020 issues panel 20.05.20

Office of Health Economics

Towse 2020 antimicrobials melbourne final

Office of Health Economics

Towse cgd price transparency seminar

Office of Health Economics

OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse

Office of Health Economics

Pricing in emerging markets: options to get value for money - Adrian Towse

Office of Health Economics

% GDP spending in UK, G5 countries and OECD upper middle income countries. W...

Office of Health Economics

The role of real world data and evidence in building a sustainable & efficien...

Office of Health Economics

The aim of this educational symposium was to discuss why we should seek value across the health care system and how we can apply existing research methods to measure the value of services. While considerable political attention in developed countries continues to be focused on drug spending, there is also growing awareness of the significant contribution of non-drug components of health care (e.g., hospital services and inefficient care delivery) to overall spending growth and patient affordability. At the same time, there is growing interest in making greater use of value assessment and value-based payment to control spending and better align it with care quality. In order to promote greater value, and to do so in ways that respond to the needs of payers and patients, it is essential to assess value across both drug- and non-drug interventions and health care services. This panel will offer expert viewpoints to identify and discuss gaps in value information, rationale and approaches to track and reduce system-wide low value care, and research methods for how to measure health care services.

ISPOR Education Symposium- Go where the money is

Office of Health Economics

Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...

Office of Health Economics

IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?

Office of Health Economics

This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes

Ispor 2019 poster - Patricia Cubi-Molla

Office of Health Economics

Understanding what aspects of health and quality of life are important to people

Office of Health Economics

Koonal presented as part of an organised session on ‘moving beyond conventional economic approaches in palliative and end of life care’. He summarised the empirical evidence on the extent of pubic support for an end of life premium, before discussing some novel approaches that have been used in recent studies. His presentation was discussed by Helen Mason of Glasgow Caledonian University. Author(s) and affiliation(s): Koonal Shah, Office of Health Economics Event: iHEA Congress Date: 17/07/2019 Location: Basel, Switzerland

Novel approaches for valuing health at the end of life

Office of Health Economics

This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run. Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London) Event: HTAi 2019 Annual Meeting Date: 18/06/2019 Location: Cologne, Germany

Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...

Office of Health Economics

There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance (AMR), but there is little agreement on how. This poster reports findings from a literature review, expert interviews and face-to-face discussions at a Forum on the current HTA and payment systems for antibiotics across Europe and a number of recommendations for adapting these systems to respond to the challenges of AMR. Author(s) and affiliation(s): Margherita Neri (OHE) Grace Hampson (OHE) Christopher Henshall (OHE visiting fellow, independent consultant) Adrian Towse (OHE) Event: HTAi annual conference 2019 Date: 18/06/2019 Location: Cologne, Germany

HTA and payment mechanisms for new drugs to tackle AMR

Office of Health Economics

This study aims to guide access decisions and drive the discussion on access and price, through recognition of the dynamic nature of value added by pharmaceutical innovation over the long-run. The analysis of the life-cycle value of risperidone estimates the value generated in the UK and Sweden. Results show that health systems were able to appropriate most of the life-cycle value generated, and this is larger than estimated at launch. Author(s) and affiliation(s): Mikel Berdud(1), Niklas Wallin-Bernhardsson(2), Bernarda Zamora(1), Peter Lindgren(2), and Adrian Towse(1) (1) Office of Health Economics (2) The Swedish Institute for. Health Economics Event: XXXIX JORNADAS DE ECONOMÍA DE LA SALUD Date: 12/06/2019 Location: Albacete, Spain

Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...

Office of Health Economics

Prescribed Specialised Services (PSS) Commissioning for Quality and Innovation (CQUIN) schemes were launched in 2013 in England with the aim of improving the quality of specialised care and achieving value for money. During this presentation, Marina Rodes Sanchez described the key features of the schemes and discussed its strengths and weaknesses based on international pay-for-performance literature. Author(s) and affiliation(s): Yan Feng, Queen Mary University of London; Søren Rud Kristensen, Imperial College London; Paula Lorgelly, King’s College London; Rachel Meacock, University of Manchester; Marina Rodes Sanchez, Office of Health Economics; Luigi Siciliani, University of York; Matt Sutton, University of Manchester Event: XXXIX Spanish Health Economics Association Conference Date: 12/06/2019 Location: Albacete, Spain

Pay for Performance for Specialised Care in England

Office of Health Economics

In this session, Meng Li sets out estimates of real option value for drugs arguing that option value matters and can be calculated. Adrian Towse sets out likely payer concerns about incorporating real option value into decision making. Meng Li responds to these concerns. Jens Grueger sets out how industry considers investment opportunities, arguing that if patients (and society) have preferences these need to be reflected in P&R decisions. Author(s) and affiliation(s): Meng Li, Postdoctoral Research Fellow, Leonard D Schaeffer Center, University of Southern California, Los Angeles, CA, USA. Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Jens Grueger, formerly Head of Global Access, Senior Vice President at F. Hoffmann-La Roche Event: ISPOR 2019 Location: New Orleans, USA Date: 21/05/2019

Real option value drugs: is it really an option?

Office of Health Economics

In this ISPOR session Chuck Phelps and Adrian Towse debated the case for and against using MCDA to support HTA decision making, as compared to weighting or augmenting a QALY based ICER approach. Chuck Phelps argued for use of MCDA, Adrian Towse for weighting the QALY. Nancy Devlin set the scene and moderated. Author(s) and affiliation(s): Nancy Devlin, Director, Centre for Health Policy, University of Melbourne, Australia Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Chuck Phelps, University of Rochester, Rochester, NY USA Event: ISPOR 2019 Location: New Orleans, USA Date: 21/05/2019

MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...

Office of Health Economics

More from Office of Health Economics (20)

Annual lecture

Devlin ispor 2020 issues panel 20.05.20

Towse 2020 antimicrobials melbourne final

Towse cgd price transparency seminar

OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse

Pricing in emerging markets: options to get value for money - Adrian Towse

% GDP spending in UK, G5 countries and OECD upper middle income countries. W...

The role of real world data and evidence in building a sustainable & efficien...

ISPOR Education Symposium- Go where the money is

Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...

IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?

Ispor 2019 poster - Patricia Cubi-Molla

Understanding what aspects of health and quality of life are important to people

Novel approaches for valuing health at the end of life

Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...

HTA and payment mechanisms for new drugs to tackle AMR

Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...

Pay for Performance for Specialised Care in England

Real option value drugs: is it really an option?

MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...

Waiting Time Policies in the Health Sector

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (8)

More from Office of Health Economics

More from Office of Health Economics (20)

Recently uploaded

Recently uploaded (17)